📊 NUTX Key Takeaways
Is Nutex Health Inc. (NUTX) a Good Investment?
Nutex Health demonstrates exceptional revenue growth (+82% YoY) with fortress-like fundamentals: excellent net margins (21.6%), strong free cash flow generation ($74.3M, 34.3% FCF margin), and minimal financial leverage (0.07x D/E). However, flat net income growth despite surging revenue suggests margin compression or prior-year timing issues requiring monitoring.
Nutex Health shows exceptional revenue growth with strong gross and operating margins, translating into robust free cash flow and supported by a highly liquid, low-leverage balance sheet. Despite flat net income YoY, operating performance and cash generation indicate healthy core fundamentals; sustaining growth without margin or reimbursement pressure is the key.
Why Buy Nutex Health Inc. Stock? NUTX Key Strengths
- Exceptional revenue growth of 82% YoY demonstrates strong market demand and business traction
- Excellent profitability metrics: 21.6% net margin, 37.5% operating margin, and 42.4% gross margin
- Strong free cash flow generation of $74.3M (34.3% FCF margin) indicates genuine earnings quality and operational efficiency
- Fortress balance sheet with minimal debt (0.07x D/E), substantial cash position ($207.3M), and exceptional liquidity (3.14x current ratio)
- Asset-light business model evidenced by minimal capex requirements ($1.2M) and high cash conversion
- Rapid revenue growth with strong operating leverage
- High cash conversion and FCF margin (~28%)
- Excellent liquidity, minimal debt, and high interest coverage
NUTX Stock Risks: Nutex Health Inc. Investment Risks
- Net income growth flat at 0% YoY despite 82% revenue growth signals potential margin compression, operational leverage challenges, or prior-year comparison distortion
- Low return on assets (4.9%) relative to $957.3M asset base suggests significant assets may not be generating attractive returns
- Rapid 82% growth trajectory presents sustainability risks and potential execution challenges at scale
- Elevated insider trading activity (21 Form 4 filings in 90 days) warrants monitoring for potential insider selling pressure
- Sustainability of 80%+ revenue growth and potential reliance on expansion or acquisitions
- Flat net income despite revenue surge suggests nonrecurring items or below-the-line pressures
- Healthcare reimbursement and payer-mix/regulatory changes could compress margins and cash flow
Key Metrics to Watch
- Net income and EPS growth trajectory in subsequent quarters to confirm margin sustainability
- Gross margin and operating margin trends through growth phase to detect further compression
- Return on Assets improvement as revenue scales to validate capital efficiency
- Free cash flow consistency and conversion rates to confirm cash generation quality
- Insider transaction patterns - magnitude and direction of insider trading activity
- Operating margin
- Cash conversion (OCF / Net Income)
Nutex Health Inc. (NUTX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 34.3% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. Strong liquidity with a 3.14x current ratio provides a solid financial cushion.
NUTX Profit Margin, ROE & Profitability Analysis
NUTX vs Services Sector: How Nutex Health Inc. Compares
How Nutex Health Inc. compares to Services sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Nutex Health Inc. Stock Overvalued? NUTX Valuation Analysis 2026
Based on fundamental analysis, Nutex Health Inc. appears fundamentally strong relative to the Services sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Nutex Health Inc. Balance Sheet: NUTX Debt, Cash & Liquidity
NUTX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Nutex Health Inc.'s revenue has grown significantly by 4,557% over the 5-year period, indicating strong business expansion. The most recent EPS of $-10.39 indicates the company is currently unprofitable.
NUTX Revenue Growth, EPS Growth & YoY Performance
NUTX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $211.8M | $21.2M | $3.33 |
| Q3 2025 | $78.8M | -$8.8M | $-1.72 |
| Q2 2025 | $76.1M | -$364.0K | $-0.07 |
| Q1 2025 | $67.5M | -$364.0K | $-0.08 |
| Q3 2024 | $62.7M | -$5.5M | $-1.25 |
| Q2 2024 | $58.9M | -$364.0K | $-0.07 |
| Q1 2024 | $56.3M | -$364.1K | $-0.01 |
| Q3 2023 | $28.4M | -$5.5M | $-0.01 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Nutex Health Inc. Dividends, Buybacks & Capital Allocation
NUTX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Nutex Health Inc. (CIK: 0001479681)
📋 Recent SEC Filings
❓ Frequently Asked Questions about NUTX
What is the AI rating for NUTX?
Nutex Health Inc. (NUTX) has a Combined AI Rating of BUY from Claude (BUY) and ChatGPT (BUY) with 72% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are NUTX's key strengths?
Claude: Exceptional revenue growth of 82% YoY demonstrates strong market demand and business traction. Excellent profitability metrics: 21.6% net margin, 37.5% operating margin, and 42.4% gross margin. ChatGPT: Rapid revenue growth with strong operating leverage. High cash conversion and FCF margin (~28%).
What are the risks of investing in NUTX?
Claude: Net income growth flat at 0% YoY despite 82% revenue growth signals potential margin compression, operational leverage challenges, or prior-year comparison distortion. Low return on assets (4.9%) relative to $957.3M asset base suggests significant assets may not be generating attractive returns. ChatGPT: Sustainability of 80%+ revenue growth and potential reliance on expansion or acquisitions. Flat net income despite revenue surge suggests nonrecurring items or below-the-line pressures.
What is NUTX's revenue and growth?
Nutex Health Inc. reported revenue of $216.5M.
Does NUTX pay dividends?
Nutex Health Inc. does not currently pay dividends.
Where can I find NUTX SEC filings?
Official SEC filings for Nutex Health Inc. (CIK: 0001479681) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is NUTX's EPS?
Nutex Health Inc. has a diluted EPS of $6.52.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is NUTX a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Nutex Health Inc. has a BUY rating with 72% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is NUTX stock overvalued or undervalued?
Valuation metrics for NUTX: ROE of 13.5% (sector avg: 16%), net margin of 21.6% (sector avg: 10%). Compare these metrics with sector averages to assess valuation.
Should I buy NUTX stock in 2026?
Our dual AI analysis gives Nutex Health Inc. a combined BUY rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is NUTX's free cash flow?
Nutex Health Inc.'s operating cash flow is $75.5M, with capital expenditures of $1.2M. FCF margin is 34.3%.
How does NUTX compare to other Services stocks?
Vs Services sector averages: Net margin 21.6% (avg: 10%), ROE 13.5% (avg: 16%), current ratio 3.14 (avg: 1.5).